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Objective: Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by impairment in social 
skills and communication with repetitive behaviors. Etiology is still unclear although it is thought to develop with inter-
action of genes and environmental factors. Oxytocin has extensive effects on intrauterine brain development. Vitamin 
D, affects neural development and differentiation and contributes to the regulation of around 900 genes including oxy-
tocin receptor gene. In the present study, the contribution of D vitamin receptor and oxytocin receptor gene poly-
morphisms in the development of ASD in Turkish community was investigated. To our knowledge, this is the first study 
examining these two associated genes together in the literature.
Methods: Eighty-five patients diagnosed with ASD according to DSM-5 who were referred to outpatient clinics of Child 
and Adolescent Psychiatry of Başkent University and Mersin University and 52 healthy, age and gender-matched con-
trols were included in the present study. Vitamin D receptor gene rs731236 (Taq1), rs2228570 (Fok1), rs1544410 
(Bsm1), rs7975232 (Apa1) polymorphisms and oxytocin receptor gene rs1042778 and rs2268493 polymorphisms were 
investigated using real time polymerase chain reaction method. 
Results: No significant difference between groups in terms of distribution of genotype and alleles in each of poly-
morphisms for these genes could be found. 
Conclusion: Knowledge of genes and polymorphisms associated with the development of ASD may be beneficial for 
early diagnosis and future treatment. Further studies with larger populations are required to demonstrate molecular path-
ways which may play part in the development of ASD in Turkey.
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INTRODUCTION
Autism spectrum disorder (ASD) is a neurodevelop-
mental disorder involving deficits in social interaction 
along with restricted interests and repetitive and stereo-
typic patterns of behavior. The estimated prevalence of 
ASD based on the 2014 National Health Interview Survey 
was 2.24% with a more than three-fold increase since 
2000. The male to female ratio is shown to be 4:1.1) The 
widely reported increase of ASD cases has stimulated re-
search in etiology through the recent decades. 
It is currently accepted that ASD has substantial herit-
ability. Specifically, twin studies have shown a con-
cordance of 70.0% to 90.0% among monozygotic twins,2) 
with much lower rates among dizygotic twins.3,4) The risk 
for a newborn child is increased more than ten times 
when a previous sibling has an ASD.5) Genome-wide link-
age and association studies have been done to search for 
susceptibility genes for ASD and several candidate genes 
have been showed to be involved in ASD.6-11)
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Although many genetic mechanisms have been elabo-
rated in the pathogenesis of ASD, the complete picture of 
ASD pathogenesis at biochemical and genetic levels re-
mains to be identified. Supporting this view, the known 
genetic variations account for only 10.0% to 20.0% of pa-
tients with ASD.6,12,13) Therefore, rather than a single caus-
ative factor, the combination and interplay of heritability 
and environmental risk factors may be important in etiol-
ogy of ASD.13) 
Among those factors, vitamin D and oxytocin may be 
important.14-16) Vitamin D is important for neuronal em-
briyogenesis and development, immune neuromodulation, 
anti-oxidation, anti-apoptosis, neuronal differentiation 
and genetic regulation.14) Some studies suggest that chil-
dren with ASD may be deficient in vitamin D and that in-
cidence of ASD may increase in offspring of mothers with 
vitamin D deficiency in pregnancy.15) The observations 
that vitamin D, in its active form, contributes to regulation 
and expression of approximately 900 genes, most of 
which play role in brain development as well as its inter-
actions with serotonergic metabolism and oxytocinmay 
support this view.15,17,18) Contrarily, vitamin D metabo-
lism may also be affected in other pediatric neuro-devel-
opmental and neuro-psychiatric disorders and its abnor-
malities may not be specific to ASD.19-21) Also, rather than 
absolute vitamin D levels, receptor polymorphisms may 
be more important in neuropsychiatric functioning.21) 
Oxytocine (OXT) is a neuropeptide related with social 
behavior, affiliation/attachment, social memory, reward 
and reactivity to social stress in mammals.22-26) Recent 
studies suggest that OXT may also be important for social 
cognition both in healthy humans as well as those with 
ASD and that exogenous applications of OXT may affect 
social behaviors albeit temporarily.16,25-31) 
Genes for OXT and its receptor also contain vitamin D 
responsive elements (VDREs) changing their function (i.e., 
both production and response).17,18,32,33) VDREs coloc-
alize with OXT in hypothalamic neurons, both interact 
with serotonergic metabolism and genetic variations in 
both have been associated with ASD; suggesting a role in 
etiology.17,18,32-40) On the other hand; OXT levels as well 
as receptor polymorphisms may display their effects in-
dependent of the ASD diagnosis41,42) and changes in VDR 
were also reported for patients with ADHD.43) 
Converging lines of evidence suggest that vitamin D, 
VDR, OXT and its receptors may play roles in social 
behaviors.15-18,22-43) As far as we are aware, no study up to 
now attempted to evaluate polymorphisms in both VDR 
and OXTR in ASD. Therefore, we aimed to evaluate the 
contribution of VDR and OXTR gene polymorphisms in 
the development of autism spectrum disorder in a Turkish 
sample. 
METHODS
Study Center, Time Frame and Ethics 
This study was conducted between January 2015 and 
January 2017 in the Child and Adolescent Psychiatry out-
patient departments of Baskent University Faculty of 
Medicine and Mersin University Faculty of Medicine. 
Age- and gender-matched healthy controls were enrolled 
among elementary school students from two schools lo-
cated in the epidemiological catchment areas of both 
departments. The study protocol has been approved by 
local ethics committee of the study center with a protocol 
number of MEU 2014/209. Parental informed assent and 
verbal assent of the children (if applicable) were procured 
prior to study entry. All of the study procedures were in 
accordance with the Declaration of Helsinki and local 
laws and regulations. 
Inclusion and Exclusion Criteria 
Three to 18 year-old, patients with non-regressive, sim-
plex-ASD (i.e., only index case among offspring),44) ac-
cording to the Diagnostic and Statistical Manual of Mental 
Disorders, fifth edition (DSM-5) criteria,45) with a score of 
＞29.5 (i.e., above cut-off for ASD) in the Turkish version 
of the Childhood Autism Rating Scale,46) without known 
genetic syndromes (i.e., Down’s syndrome, fragile X syn-
drome, Rett syndrome) or comorbid intellectual disability 
(as evaluated with developmental tests or Turkish version 
of the Wechsler Intelligence Scale for Children, revised 
edition along with clinical interviews) were included. The 
patients included those with autistic disorder, Asperger’s 
disorder and pervasive developmental disorder-not other-
wise specified (PDD-NOS) according to DSM fourth edi-
tion, text revision (DSM-IV-TR) criteria. The patients 
should also be free of of comorbid chronic medical and 
neurological disorders. Healthy controls should be free of 
life-time psychopathology as evaluated via Turkish ver-
sion of the Kiddie Schedule for Affective Disorders and 
Schizophrenia for School Aged Children-Present/Lifetime 
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Table 2. Genotype and allele frequencies of children with autism spectrum disorder (ASD) and healthy controls for vitamin D and oxytocine receptors
Gene SNP
Genotype frequency
p*
Allele frequency
p*Healthy control ASD Healthy control ASD 
1/1 1/2 2/2 1/1 1/2 2/2 1 2 1 2
VDR rs731236 
(Taq1)
21 (40.4) 28 (53.8) 3 (5.8) 37 (43.5) 35 (41.2) 13 (15.3) 0.157 70 (67.3) 34 (32.7) 109 (64.1) 61 (35.9) 0.590
VDR rs2228570 
(Fok1)
4 (7.7) 20 (38.5) 28 (53.8) 5 (5.9) 31 (36.5) 49 (57.6) 0.870 28 (26.9) 76 (73.1) 41 (24.1) 129 (75.9) 0.604
VDR rs1544410 
(Bsm1)
6 (11.5) 26 (50.0) 20 (38.5) 11 (12.9) 40 (47.1) 34 (40.0) 0.938 38 (36.5) 66 (63.5) 62 (36.5) 108 (63.6) 0.991
VDR rs7975232 
(Apa1)
0 (0.0) 35 (67.3) 17 (32.7) 2 (2.4) 56 (65.9) 27 (31.8) 0.537 35 (33.7) 69 (66.3) 60 (35.3) 110 (64.7) 0.782
OXTR rs1042778 19 (36.5) 28 (53.8) 5 (9.6) 30 (35.3) 40 (47.1) 15 (17.6) 0.419 66 (63.5) 38 (36.5) 100 (58.8) 100 (58.8) 0.446
OXTR rs2268493 0 (0.0) 20 (38.5) 32 (61.5) 6 (7.1) 28 (32.9) 51 (60.0) 0.138 20 (19.2) 84 (80.8) 40 (23.5) 130 (76.5) 0.404
Values are presented as number (%).
*Hardy-Weinberg test.
Table 1. Sociodemographic variables of children with autism spectrum
disorder (ASD) and healthy controls
Variable ASD (n=85) Healthy controls (n=52) p value
Age (yr) 7.38±4.01 7.46±3.87 0.903
Sex
Male 72 (84.7) 39 (75.0) 0.160
Female 13 (15.3) 13 (25.0)
Mother’s age (yr) 34.98±6.51 38.94±6.35 0.001*
Father’s age (yr) 38.37±9.38 37.41±14.14 0.634
Number of siblings 2 (1-2) 2 (1-3) 0.007*
Order of birth 2 (2-3) 1 (1-2) 0.002*
Values are presented as mean±standard deviation, number (%), or 
median (range).
*Mann-Whitney U or t tests.
Version (K-SADS-PL).47) Parental informed consent and 
verbal assent of children (if applicable) were necessary for 
inclusion. 
Power Analysis 
Under a multiplicative model with significance level of 
0.05 (not corrected for multiple comparisons), a disease 
prevelance of 1.0%, genotype relative risk of 1.2, disease 
allele frequency of 20.0% and at 1:1 case-to-control ratio 
we would need 2,000 cases for 70.0% power.48-50) Within 
the time-frame and considering our load of patients with 
ASD we settled for 100 cases with ASD and 100 controls 
(i.e., 41.0% power). In the end we could enroll 85 patients 
with ASD and 52 controls leading to a power of approx-
imately 30.0%. 
Laboratory Analysis
In both groups, DNA was extracted from peripheral 
blood transferred to ethilen dianmin acetic acid tubes. 
Genomic DNA was extracted from peripheral blood by 
using GF-1 blood DNA extraction kit (Vivantis 
TechnologiesTM, Oceanside, CA, USA) according to the 
manufacturer’s instructions. VDR rs731236 (Taq1), 
rs2228570 (Fok1), rs1544410 (Bsm1) rs7975232 (Apa1) 
polymorphisms and OXTR rs1042778 and rs2268493 
polymorphisms genotyping was performed with the 
TaqManⓇ SNP Genotyping Assay (Applied Biosystems, 
Foster City, CA, USA). The polymerase chain reaction 
(PCR) reactions were carried out in a total volume of 25 L 
containing TaqManⓇ Genotyping Master Mix, TaqManⓇ 
Genotyping AssayMix, DNase-free water and genomic 
DNA. The PCR conditions were 10 minutes at 95°C, fol-
lowed by 40 cycles at 95°C for 15 seconds and 60°C for 1 
minutes. The 96-well ABI 7500 Fast Real-Time PCR sys-
tem was applied (Applied Biosystems).
Statistical Analysis 
In statistical analysis, SPSS ver. 11.5 (SPSS Inc., 
Chicago, IL, USA.) and MedCalc Statistical software ver-
sion 10.4 (MedCacl Software bvba, Ostend, Belgium) pro-
grams were used. For comparisons between groups, chi 
square test, t test for independent samples and Mann- 
Whitney U tests were used and results were evaluated 
with 95.0% confidence intervals and p＜0.05 was con-
sidered statistically significant. All comparisons were 
two-tailed. Bonferroni adjustment was undertaken for 
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multiple comparisons. Whether population distribution 
was balanced in ASD and control groups was analyzed 
with Hardy-Weinberg test.
RESULTS
Within the specified time-frame 85 patients with a 
mean age of 7.38±4.01 years (84.7% male) and 52 
healthy controls with a mean age of 7.46±3.87 years 
(75.0% male) could be enrolled. The groups were similar 
in terms of mean age and gender ratios (p=0.903 and 
0.160; respectively) (Table 1).
Control subjects were significantly more likely to be 
first born and had more siblings. Their mothers were also 
significantly older than those of children with ASD.
Genotyping results of patients andhealthy controls in-
cluded in the study are summarized in Table 2.
VDR-Taq I displayed Hardy-Weinberg equilibrium on-
ly in patients with ASD (p=0.30) but did not display it in 
controls (p=0.03). All other SNPs of VDR were in equili-
brium for both controls and patients with ASD. For OXTR 
SNPs only rs2268493 was not in equilibrium and only for 
controls (p=0.02). All other SNPs were in equilibrium. 
No significant differences could be found between 
groups in terms of genotypes and allelles. 
DISCUSSION
This multi-center, cross-sectional, case-control study 
on polymorphisms of VDR and OXTR in age- and gen-
der-matched patients with ASDs and healthy controls 
could not find a significant difference between groups. 
ASD is a heterogeneous disorder that is characterized 
by impaired social communications/interactions, and re-
stricted, repetitive behaviors. Latest prevalence figures cit-
ed were as high as 1 in 88 which denotes an increase of 
600.0% from 1970s. The cause of this increase is still not 
entirely known, although earlier recognition and de-
tection of milder cases on the spectrum were frequently 
listed as major contributors.51,52) 
The increase in ASD prevalence has stimulated re-
search on its genetic basis. Changes in at least 440 genes 
were reported in etiology. Of these, 7.0% to 20.0% in-
clude changes in number of copies, 5.0% to 7.0% involve 
polymorphisms in a single gene, and 5.0 % are single 
gene mutations associated with metabolic diseases.6,53)
Changes in levels of vitamin D as well as genetic varia-
tions in its metabolism as well as interaction with oxytocin 
were posited to play a role in ASD etiology.14,15) Vitamin 
D, in its active form plays role in brain development and 
functioning17,18) and interacts with serotonin and oxy-
tocin,15,21,33,39) supporting a potential role in ASD. 
Previous reviews suggested that genetic variations affect-
ing vitamin D levels and functioning could play a role in 
ASD.54) Schmidt et al.40) reported that VDR poly-
morphisms especially. TaqI and BsmI could be associated 
with ASD risk.40) In another, recent study from Turkey, 
FokI, TaqI, and BsmI genotypes for VDR differed sig-
nificantly between children with ASD and healthy 
controls.39) An earlier study however, failed to find an 
association.43) In our study we also could not find an asso-
ciation between SNP at VDR (TaqI, FokI, BsmI, and ApaI) 
and a diagnosis of ASD. This negative result may be due to 
low power of our study. Indeed, a post-hoc power analy-
sis revealed that we could only achieve 30.0% power to 
refute the null hypothesis. Alternatively, our sampling 
method for simplex, non-regressive ASD cases may be in-
adequate (i.e., dependence on personal reports and pe-
diatric consultations, lack of genetic testing for specific 
syndromes). Also, there may be false negatives among our 
sample due to “stoppage phenomenon”.7,44) The patients 
as a whole varied in severity and included those who 
would be diagnosed with either autistic disorder, 
Asperger syndrome or PDD-NOS as per DSM-IV-TR 
criteria. This heterogeneity may have also affected our 
results. VDR TaqI and OXTR rs2268493 polymorphisms 
were also not in equilibrium among controls and this may 
have affected the results. 
Variations in OXT function are also suggested among 
etiologies for ASDs.16,23,29-31) SNPs in OXTR are known to 
affect social functions37,41) even without a formal diag-
nosis of ASD. Vitamin D also interacts with oxytocin in 
neural functioning.17,18) SNP rs1042778 at OXTR may in-
crease social impairment in ASD36,37) while rs2268493 
may affect speech and repetitive movements in addition 
to social skills in ASD.37,38) As for discrete diagnostic enti-
ties, rs2268493 was found to be associated with Asperger 
syndrome55) while rs2268493 and rs1042778 were found 
to be associated with ASD.37,38,56) However, a study from 
Japan failed to replicate the association of those poly-
morphisms with ASD.57) We also failed to replicate this 
association. This may be due to heterogeneous and lim-
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ited samples as well as low power. Our results should be 
confirmed with further studies on larger samples. 
Finally, controls in our sample had more siblings and 
were more likely to be first born offspring of their mothers 
while patients with ASD had significantly younger 
mothers. While the first finding may be related to the 
“stoppage phenomenon” and the stresses of caring for a 
child with ASD, the second observation needs explana-
tion.44) We tried to sample simplex families which may se-
lect especially for copy number variations (CNVs) in 
etiology.2-7,44) While increasing parental age is known to 
be related with changes in germ cells and de novo CNVs, 
recent findings suggest that early parenthood may also be 
related with changes in germ cell lines.58,59) Our findings 
may reflect those observations although lack of genetic 
testing of parents in our sample precludes more definite 
hypotheses. The effects of early-parenthood on risk for 
ASD in offspring should be evaluated with further studies.
This multi-center, case-control study of SNPs in OXTR 
and VDR in ASD failed to find a significant association. 
The results may be affected by limited sample size and 
power and inadequate sampling of simplex cases. Further 
studies on larger ASD samples, preferably from differing 
geographical regions of Turkey are needed for con-
firmation of our results. 
This project was supported by TUBITAK (The Scientific 
and Technological Research Council of Turkey, Project 
No: 115S864).
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